UNSPSC 51124501: Moracizine or moricizine

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C22H25N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2GT1D0TMX1, chemically known as phenothiazine-2-carbamic acid, 10-(3-morpholinopropionyl)-, ethyl ester but more generally known as moracizine, which bears US NIH Compound Identifier 34633. European Medicines Agency schedules Moracizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09062MIG.

UNSPSC 51124501 Moracizine or moricizine is a Commodity code that in practice covers emergency medical and pharmacy supply procurement by state and local health agencies, fire departments, and cooperative purchasing alliances. Recent state and local solicitations show government buying advanced life support medications, generic pharmaceuticals, and OTC products through sealed competitive bids and cooperative purchasing vehicles. The City of Tampa Fire Rescue, Texas Health and Human Services Commission, and multistate cooperative purchasing alliances are the primary issuing bodies active under this code, reflecting demand from municipal emergency services, state health programs, and interstate pharmaceutical procurement consortia. Vendors must meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance where applicable, comprehensive insurance requirements, and product shelf-life guarantees—typically nine months to one year from acceptance or manufacture.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's IFB for Advanced Life Support Medications (26P00188), due April 8, 2026, sought 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem with one-year contract terms and renewal options; the estimated value was $40,000 and included a 5 percent Small Local Business Enterprise (SLBE) sheltered market discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) requiring submission through three authorized wholesalers and covering participating state and local facilities across multiple states including Oregon; contract terms extended through June 30, 2028 for incumbents. Texas HHS issued an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. All solicitations require Safety Data Sheets, accessibility documentation, and demonstrated capacity to meet government procurement timelines and compliance standards.